# Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

> **NCT02895906** · PHASE1 · COMPLETED · sponsor: **Aevi Genomic Medicine, LLC, a Cerecor company** · enrollment: 2 (actual)

## Conditions studied

- 22q11.2 Deletion Syndrome

## Interventions

- **DRUG:** NFC-1

## Key facts

- **NCT ID:** NCT02895906
- **Lead sponsor:** Aevi Genomic Medicine, LLC, a Cerecor company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-28
- **Primary completion:** 2017-04-13
- **Final completion:** 2017-04-20
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02895906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02895906, "Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02895906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*